GlycoMimetics, Inc.

GlycoMimetics is a publicly traded, clinical-stage biotechnology company that utilizes novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs.Our Management Team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.Since the company’s inception in 2003, GlycoMimetics has developed a robust, diversified product pipeline.The company’s goal is to be the leader in the discovery, development and commercialization of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

Bank Name GlycoMimetics, Inc.
Stock Exchange NASDAQ
Symbol GLYC
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
CEO Ms. Rachel K. King
Employees 40
Registered Year 2003